Ars Technica NewsOct 21
FDA slows down on drug reviews, approvals amid Trump admin chaos https://arstechni.ca/Go9U #drugapprovals #reviews #Health #fda
FDA slows down on drug reviews, approvals amid Trump admin chaos

The ongoing shutdown also means no new drug submissions are being accepted.

Ars Technica
prahicmiJan 10, 2025

Cephalosporin: Powerful antibiotics against bacterial infections

Cephalosporin Drugs exert their antibacterial effect by inhibiting the transpeptidation and transglycosylation reactions of the peptidoglycan layer synthesis in bacterial cell walls.

Cephalosporin Drugs- https://justpaste.me/W7t32

#CoherentMarketInsights #BetalactamAntibiotics #AntipseudomonalCoverage #DrugApprovals #ClinicalTrials

Cephalosporin Drugs: An Overview of their Uses

Cephalosporin drugs are a group of antibiotics that contain a beta-lactam ring structure in their molecular structure. They are synthesized ...

Just Paste Me
Stonk Broker Live NewsFeb 14, 2023
Billionaire Mark Cuban Offers Solution to Bernie Sanders Outrage

https://www.thestreet.com/prices/billionaire-mark-cuban-offers-solution-to-bernie-sanders-outrage

#Pharmaceuticals #HealthInsurance #PERSONALFINANCE #DrugApprovals #Technology #Economics #Investing #INVESTING #Politics #Economy #Health #Prices
Stonk Broker Live NewsFeb 2, 2023
Eli Lilly Tops Q4 Earnings Forecast, Lifts 2023 Outlook, On Trulicity Strength

https://www.thestreet.com/markets/eli-lilly-tops-q4-profit-forecast-on-continued-trulicity-strength

#StockMarketFutures #Pharmaceuticals #DrugApprovals #Investing #INVESTING #EARNINGS #Earnings #Consumer #FUTURES #MARKETS #Markets #STOCKS #Stocks
Stonk Broker Live NewsFeb 2, 2023
Merck Stock Slumps As 2023 Profit Outlook Clouds Q4 Earnings Beat

https://www.thestreet.com/markets/merck-stock-slumps-as-2023-profit-outlook-clouds-q4-earnings-beat

#StockMarketFutures #Pharmaceuticals #DrugApprovals #INVESTING #Investing #Earnings #Consumer #EARNINGS #FUTURES #MARKETS #Markets #STOCKS #Stocks
Stonk Broker Live NewsJan 31, 2023
Pfizer Stock Slides As Soft Covid Vaccine Sales Outlook Mars Q4 Earnings Beat

https://www.thestreet.com/markets/pfizer-stock-slides-as-soft-covid-vaccine-outlook-mars-profit-beat

#StockMarketFutures #Pharmaceuticals #DrugApprovals #INVESTING #Investing #EARNINGS #COVID-19 #Earnings #Consumer #FUTURES #MARKETS #Markets #STOCKS #Stocks
Pfizer Stock Slides As Soft Covid Vaccine Sales Outlook Mars Q4 Earnings Beat

Pfizer shares traded lower Tuesday after the drugmaker posted stronger-than-expected fourth quarter earnings but a softer 2023 growth forecast thanks to waning sales for its Covid treatments.

TheStreet
Stonk Broker Live NewsJan 18, 2023
Elon Musk Says Living Past 100 Is Not Good

https://www.thestreet.com/technology/elon-musk-says-living-past-100-is-not-good

#ElectricVehicles #Pharmaceuticals #DrugApprovals #LifeSciences #TECHNOLOGY #Technology #Automotive #INVESTING #ElonMusk #Biotech #Tesla
Elon Musk Says Living Past 100 Is Not Good

The CEO of Tesla and SpaceX promises that humans will soon live on Mars. But his technological ambitions have limits.

TheStreet
Stonk Broker Live NewsJan 18, 2023
Elon Musk Takes Sides in the Immortality Debate

https://www.thestreet.com/technology/elon-musk-takes-sides-on-the-immortality-debate

#ElectricVehicles #Pharmaceuticals #DrugApprovals #LifeSciences #TECHNOLOGY #Technology #Automotive #INVESTING #ElonMusk #Biotech #Tesla
Elon Musk Takes Sides in the Immortality Debate

The CEO of Tesla and SpaceX promises that humans will soon live on Mars. But his technological ambitions have limits.

TheStreet
Stonk Broker Live NewsJan 18, 2023
Moderna Stock Leaps On Positive Data From Late-Stage RSV Vaccine Trial

https://www.thestreet.com/markets/moderna-stock-leaps-on-positive-data-from-rsv-vaccine-trial

#StockMarketFutures #Pharmaceuticals #DrugApprovals #INVESTING #Investing #EARNINGS #Earnings #Finance #FUTURES #MARKETS #Markets #Stocks #STOCKS
Moderna Stock Leaps On Positive Data From Late-Stage RSV Vaccine Trial

Moderna shares moved firmly higher Wednesday after the drugmaker unveiled positive data from a late stage trial of its developing respiratory syncytial virus treatment.

TheStreet
Stonk Broker Live NewsJan 5, 2023
Mark Cuban's Plans Pose Major Threat to CVS and Walgreens

https://www.thestreet.com/retail/mark-cubans-plans-pose-major-threat-to-cvs-and-walgreens

#ConsumerServices #ConsumerProducts #Pharmaceuticals #DrugApprovals #Technology #TECHNOLOGY #E-Commerce #LIFESTYLE #INVESTING #Investing #Medicare #Consumer #Economy #HEALTH #Retail #Stocks
Mark Cuban's Plans Pose Major Threat to CVS and Walgreens

In an interview with TheStreet, the entrepreneur said he wanted to lower drug prices even further and expand his online pharmacy's customer base.

TheStreet